| Year |
Citation |
Score |
| 2022 |
Leandro J, Khamrui S, Suebsuwong C, Chen PJ, Secor C, Dodatko T, Yu C, Sanchez R, DeVita RJ, Houten SM, Lazarus MB. Characterization and structure of the human lysine-2-oxoglutarate reductase domain, a novel therapeutic target for treatment of glutaric aciduria type 1. Open Biology. 12: 220179. PMID 36128717 DOI: 10.1098/rsob.220179 |
0.633 |
|
| 2021 |
He Z, Chen L, Catalan-Dibene J, Bongers G, Faith JJ, Suebsuwong C, DeVita RJ, Shen Z, Fox JG, Lafaille JJ, Furtado GC, Lira SA. Food colorants metabolized by commensal bacteria promote colitis in mice with dysregulated expression of interleukin-23. Cell Metabolism. PMID 33989521 DOI: 10.1016/j.cmet.2021.04.015 |
0.531 |
|
| 2021 |
Kumar K, Suebsuwong C, Wang P, Garcia-Ocana A, Stewart AF, DeVita RJ. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes. Journal of Medicinal Chemistry. PMID 33682417 DOI: 10.1021/acs.jmedchem.0c02050 |
0.68 |
|
| 2020 |
Leandro J, Khamrui S, Wang H, Suebsuwong C, Nemeria NS, Huynh K, Moustakim M, Secor C, Wang M, Dodatko T, Stauffer B, Wilson CG, Yu C, Arkin MR, Jordan F, et al. Inhibition and Crystal Structure of the Human DHTKD1-Thiamin Diphosphate Complex. Acs Chemical Biology. PMID 32633484 DOI: 10.1021/Acschembio.0C00114 |
0.682 |
|
| 2020 |
Suebsuwong C, Dai B, Pinkas DM, Duddupudi AL, Li L, Bufton JC, Schlicher L, Gyrd-Hansen M, Hu M, Bullock AN, Degterev A, Cuny GD. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. European Journal of Medicinal Chemistry. 200: 112417. PMID 32505849 DOI: 10.1016/J.Ejmech.2020.112417 |
0.669 |
|
| 2018 |
Hrdinka M, Schlicher L, Dai B, Pinkas DM, Bufton JC, Picaud S, Ward JA, Rogers C, Suebsuwong C, Nikhar S, Cuny GD, Huber KV, Filippakopoulos P, Bullock AN, Degterev A, et al. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. The Embo Journal. PMID 30026309 DOI: 10.15252/Embj.201899372 |
0.658 |
|
| 2018 |
Suebsuwong C, Pinkas DM, Ray SS, Bufton JC, Dai B, Bullock AN, Degterev A, Cuny GD. Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 29409752 DOI: 10.1016/J.Bmcl.2018.01.044 |
0.672 |
|
| 2017 |
Cuny GD, Suebsuwong C, Ray SS. Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016). Expert Opinion On Therapeutic Patents. PMID 28074661 DOI: 10.1080/13543776.2017.1280463 |
0.671 |
|
| 2015 |
Canning P, Ruan Q, Schwerd T, Hrdinka M, Maki JL, Saleh D, Suebsuwong C, Ray S, Brennan PE, Cuny GD, Uhlig HH, Gyrd-Hansen M, Degterev A, Bullock AN. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors. Chemistry & Biology. 22: 1174-84. PMID 26320862 DOI: 10.1016/J.Chembiol.2015.07.017 |
0.678 |
|
| 2015 |
Najjar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL, Nogusa S, Shah S, Saleh D, Gough PJ, Bertin J, Yuan J, Balachandran S, Cuny GD, Degterev A. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Reports. 10: 1850-60. PMID 25801024 DOI: 10.1016/J.Celrep.2015.02.052 |
0.645 |
|
| 2015 |
Canning P, Ruan Q, Schwerd T, Hrdinka M, Maki JL, Saleh D, Suebsuwong C, Ray S, Brennan PE, Cuny GD, Uhlig HH, Gyrd-Hansen M, Degterev A, Bullock AN. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors Chemistry and Biology. DOI: 10.1016/j.chembiol.2015.07.017 |
0.608 |
|
| 2014 |
Sun Z, Khan J, Makowska-Grzyska M, Zhang M, Cho JH, Suebsuwong C, Vo P, Gollapalli DR, Kim Y, Joachimiak A, Hedstrom L, Cuny GD. Synthesis, in vitro evaluation and cocrystal structure of 4-oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase (CpIMPDH) inhibitors. Journal of Medicinal Chemistry. 57: 10544-50. PMID 25474504 DOI: 10.1021/Jm501527Z |
0.616 |
|
| Show low-probability matches. |